Neumora Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(236,928) | $(243,787) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 29,876 | 39,990 |
| Non-cash operating lease expense | 1,892 | 3,290 |
| Depreciation and amortization | 208 | 631 |
| Net accretion of investments in marketable securities | (2,934) | (5,719) |
| Impairment of held for sale assets | 595 | — |
| Loss on disposal of property and equipment | 47 | — |
| Amortization of debt issuance costs and accretion of final payment fee | 492 | — |
| Amortization and write-off of deferred debt issuance costs | 717 | — |
| Other noncash expenses | 32 | 23 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,770) | 15,905 |
| Accounts payable | 71 | 2,873 |
| Accrued liabilities | 4,195 | 7,236 |
| Operating lease liabilities | (1,880) | (3,378) |
| Other assets | (53) | — |
| Net cash used in operating activities | (206,440) | (182,936) |
| Investing activities: | ||
| Purchases of marketable securities | (82,868) | (312,223) |
| Cash paid for acquisition of assets | — | (775) |
| Proceeds from maturities of marketable securities | 251,170 | 242,441 |
| Proceeds from sale of property and equipment | 218 | — |
| Net cash provided by (used in) investing activities | 168,520 | (70,557) |
| Financing activities: | ||
| Proceeds from term loan, net | 57,161 | — |
| Proceeds from exercise of stock options | — | 7,482 |
| Proceeds from employee stock purchase plan purchases | 275 | 427 |
| Proceeds from issuance of common stock in at-the-market transactions, net of commissions and offering costs | 19,653 | 13,694 |
| Net cash provided by financing activities | 77,089 | 21,603 |
| Net change in cash and cash equivalents and restricted cash | 39,169 | (231,890) |
| Cash and cash equivalents and restricted cash at beginning of year | 143,361 | 375,251 |
| Cash and cash equivalents and restricted cash at end of period | $182,530 | $143,361 |
| Components of cash and restricted cash: | ||
| Cash and cash equivalents | $182,530 | $142,148 |
| Restricted cash | — | 1,213 |
| Total cash and cash equivalents and restricted cash | $182,530 | $143,361 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $1,501 | $— |
| Cash paid for income taxes | $323 | $473 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Principal amount of debt extinguished upon conversion to common stock | $3,950 | $— |
| Debt issuance costs reclassified to equity in connection with conversion | $112 | $— |
| Right-of-use-asset in connection with new operating lease agreement | $532 | $— |
| Operating lease liability in connection with new lease agreement | $505 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.